Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Influenza A Virus Infection Induces Viral and Cellular Defective Ribosomal Products Encoded by Alternative Reading Frames.

Zanker DJ, Oveissi S, Tscharke DC, Duan M, Wan S, Zhang X, Xiao K, Mifsud NA, Gibbs J, Izzard L, Dlugolenski D, Faou P, Laurie KL, Vigneron N, Barr IG, Stambas J, Van den Eynde BJ, Bennink JR, Yewdell JW, Chen W.

J Immunol. 2019 May 15. pii: ji1900070. doi: 10.4049/jimmunol.1900070. [Epub ahead of print]

PMID:
31092636
2.

CXCR6-Deficiency Improves the Control of Pulmonary Mycobacterium tuberculosis and Influenza Infection Independent of T-Lymphocyte Recruitment to the Lungs.

Ashhurst AS, Flórido M, Lin LCW, Quan D, Armitage E, Stifter SA, Stambas J, Britton WJ.

Front Immunol. 2019 Mar 7;10:339. doi: 10.3389/fimmu.2019.00339. eCollection 2019.

3.

Deep sequencing of primary human lung epithelial cells challenged with H5N1 influenza virus reveals a proviral role for CEACAM1.

Ye S, Cowled CJ, Yap CH, Stambas J.

Sci Rep. 2018 Oct 19;8(1):15468. doi: 10.1038/s41598-018-33605-6.

4.

Pulmonary immunization with a recombinant influenza A virus vaccine induces lung-resident CD4+ memory T cells that are associated with protection against tuberculosis.

Flórido M, Muflihah H, Lin LCW, Xia Y, Sierro F, Palendira M, Feng CG, Bertolino P, Stambas J, Triccas JA, Britton WJ.

Mucosal Immunol. 2018 Nov;11(6):1743-1752. doi: 10.1038/s41385-018-0065-9. Epub 2018 Aug 16.

PMID:
30115996
5.

Evolution of high pathogenicity of H5 avian influenza virus: haemagglutinin cleavage site selection of reverse-genetics mutants during passage in chickens.

Luczo JM, Tachedjian M, Harper JA, Payne JS, Butler JM, Sapats SI, Lowther SL, Michalski WP, Stambas J, Bingham J.

Sci Rep. 2018 Aug 1;8(1):11518. doi: 10.1038/s41598-018-29944-z.

6.

Sequential pulmonary immunization with heterologous recombinant influenza A virus tuberculosis vaccines protects against murine M. tuberculosis infection.

Muflihah H, Flórido M, Lin LCW, Xia Y, Triccas JA, Stambas J, Britton WJ.

Vaccine. 2018 Apr 25;36(18):2462-2470. doi: 10.1016/j.vaccine.2018.03.037. Epub 2018 Mar 27.

PMID:
29602704
7.

Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome.

Izzard L, Dlugolenski D, Xia Y, McMahon M, Middleton D, Tripp RA, Stambas J.

Virus Res. 2017 May 2;235:115-120. doi: 10.1016/j.virusres.2017.04.002. Epub 2017 Apr 7.

8.

ADAMTS5 Is a Critical Regulator of Virus-Specific T Cell Immunity.

McMahon M, Ye S, Izzard L, Dlugolenski D, Tripp RA, Bean AG, McCulloch DR, Stambas J.

PLoS Biol. 2016 Nov 17;14(11):e1002580. doi: 10.1371/journal.pbio.1002580. eCollection 2016 Nov.

9.

Recombinant influenza virus expressing HIV-1 p24 capsid protein induces mucosal HIV-specific CD8 T-cell responses.

Tan HX, Gilbertson BP, Jegaskanda S, Alcantara S, Amarasena T, Stambas J, McAuley JL, Kent SJ, De Rose R.

Vaccine. 2016 Feb 24;34(9):1172-9. doi: 10.1016/j.vaccine.2016.01.030. Epub 2016 Jan 28.

PMID:
26826545
10.

Molecular pathogenesis of H5 highly pathogenic avian influenza: the role of the haemagglutinin cleavage site motif.

Luczo JM, Stambas J, Durr PA, Michalski WP, Bingham J.

Rev Med Virol. 2015 Nov;25(6):406-30. doi: 10.1002/rmv.1846. Epub 2015 Oct 15. Review.

11.

Inhibition of reactive oxygen species production ameliorates inflammation induced by influenza A viruses via upregulation of SOCS1 and SOCS3.

Ye S, Lowther S, Stambas J.

J Virol. 2015 Mar;89(5):2672-83. doi: 10.1128/JVI.03529-14. Epub 2014 Dec 17.

12.

Epitope-specific CD4+, but not CD8+, T-cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection.

Flórido M, Pillay R, Gillis CM, Xia Y, Turner SJ, Triccas JA, Stambas J, Britton WJ.

Eur J Immunol. 2015 Mar;45(3):780-93. doi: 10.1002/eji.201444954. Epub 2014 Dec 23.

13.

miRNA modulation of SOCS1 using an influenza A virus delivery system.

Izzard L, Ye S, Jenkins K, Xia Y, Tizard M, Stambas J.

J Gen Virol. 2014 Sep;95(Pt 9):1880-5. doi: 10.1099/vir.0.063834-0. Epub 2014 May 29.

PMID:
24876306
14.

Influenza reverse genetics: dissecting immunity and pathogenesis.

Ye S, Evans JG, Stambas J.

Expert Rev Mol Med. 2014 Feb 14;16:e2. doi: 10.1017/erm.2014.4. Review.

PMID:
24528628
15.

Influenza A virus infection impairs mycobacteria-specific T cell responses and mycobacterial clearance in the lung during pulmonary coinfection.

Flórido M, Grima MA, Gillis CM, Xia Y, Turner SJ, Triccas JA, Stambas J, Britton WJ.

J Immunol. 2013 Jul 1;191(1):302-11. doi: 10.4049/jimmunol.1202824. Epub 2013 May 22.

16.

Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity.

Ranasinghe C, Trivedi S, Stambas J, Jackson RJ.

Mucosal Immunol. 2013 Nov;6(6):1068-80. doi: 10.1038/mi.2013.1. Epub 2013 Feb 13.

PMID:
23403475
17.

Promotion of Hendra virus replication by microRNA 146a.

Stewart CR, Marsh GA, Jenkins KA, Gantier MP, Tizard ML, Middleton D, Lowenthal JW, Haining J, Izzard L, Gough TJ, Deffrasnes C, Stambas J, Robinson R, Heine HG, Pallister JA, Foord AJ, Bean AG, Wang LF.

J Virol. 2013 Apr;87(7):3782-91. doi: 10.1128/JVI.01342-12. Epub 2013 Jan 23.

18.

Trivalent live attenuated influenza-simian immunodeficiency virus vaccines: efficacy and evolution of cytotoxic T lymphocyte escape in macaques.

Reece JC, Alcantara S, Gooneratne S, Jegaskanda S, Amaresena T, Fernandez CS, Laurie K, Hurt A, O'Connor SL, Harris M, Petravic J, Martyushev A, Grimm A, Davenport MP, Stambas J, De Rose R, Kent SJ.

J Virol. 2013 Apr;87(8):4146-60. doi: 10.1128/JVI.02645-12. Epub 2013 Jan 23.

19.

Glutathione peroxidase-1 reduces influenza A virus-induced lung inflammation.

Yatmaz S, Seow HJ, Gualano RC, Wong ZX, Stambas J, Selemidis S, Crack PJ, Bozinovski S, Anderson GP, Vlahos R.

Am J Respir Cell Mol Biol. 2013 Jan;48(1):17-26. doi: 10.1165/rcmb.2011-0345OC. Epub 2012 Sep 20.

PMID:
23002098
20.

Comparison of influenza and SIV specific CD8 T cell responses in macaques.

Jegaskanda S, Reece JC, De Rose R, Stambas J, Sullivan L, Brooks AG, Kent SJ, Sexton A.

PLoS One. 2012;7(3):e32431. doi: 10.1371/journal.pone.0032431. Epub 2012 Mar 5.

21.

Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens.

Meliopoulos VA, Andersen LE, Birrer KF, Simpson KJ, Lowenthal JW, Bean AG, Stambas J, Stewart CR, Tompkins SM, van Beusechem VW, Fraser I, Mhlanga M, Barichievy S, Smith Q, Leake D, Karpilow J, Buck A, Jona G, Tripp RA.

FASEB J. 2012 Apr;26(4):1372-86. doi: 10.1096/fj.11-193466. Epub 2012 Jan 12. Review.

22.

Suppressing production of reactive oxygen species (ROS) for influenza A virus therapy.

Vlahos R, Stambas J, Selemidis S.

Trends Pharmacol Sci. 2012 Jan;33(1):3-8. doi: 10.1016/j.tips.2011.09.001. Epub 2011 Oct 1. Review.

PMID:
21962460
23.

A gel-capture assay for characterizing the sialyl-glycan selectivity of influenza viruses.

Velkov T, Thompson PE, El-Kabbani O, Lindh F, Stambas J, Rockman S.

Acta Virol. 2011;55(2):131-7.

PMID:
21692561
24.

A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations.

Ranasinghe C, Eyers F, Stambas J, Boyle DB, Ramshaw IA, Ramsay AJ.

Vaccine. 2011 Apr 5;29(16):3008-20. doi: 10.1016/j.vaccine.2011.01.106. Epub 2011 Feb 23.

25.

Inhibition of Nox2 oxidase activity ameliorates influenza A virus-induced lung inflammation.

Vlahos R, Stambas J, Bozinovski S, Broughton BR, Drummond GR, Selemidis S.

PLoS Pathog. 2011 Feb 3;7(2):e1001271. doi: 10.1371/journal.ppat.1001271.

26.

Timing of immune escape linked to success or failure of vaccination.

Reece JC, Loh L, Alcantara S, Fernandez CS, Stambas J, Sexton A, De Rose R, Petravic J, Davenport MP, Kent SJ.

PLoS One. 2010 Sep 16;5(9). pii: e12774. doi: 10.1371/journal.pone.0012774.

27.

Influenza A virus-specific CD8 T-cell responses: from induction to function.

Olson M, Russ B, Doherty P, Turner S, Stambas J.

Future Virol. 2010 Mar 1;5(2):175-183.

28.

Diversity and clonotypic composition of influenza-specific CD8+ TCR repertoires remain unaltered in the absence of Aire.

Kedzierska K, Valkenburg SA, Guillonneau C, Hubert FX, Cukalac T, Curtis JM, Stambas J, Scott HS, Kedzierski L, Venturi V, Davenport MP.

Eur J Immunol. 2010 Mar;40(3):849-58. doi: 10.1002/eji.200939918.

29.

Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.

Cukalac T, Moffat JM, Venturi V, Davenport MP, Doherty PC, Turner SJ, Stambas J.

Vaccine. 2009 Nov 12;27(48):6755-61. doi: 10.1016/j.vaccine.2009.08.079. Epub 2009 Sep 8.

PMID:
19744584
30.

Finding multiple needles in one immune haystack.

Kedzierska K, Stambas J, Doherty PC.

Nat Methods. 2009 Jul;6(7):489-90. doi: 10.1038/nmeth0709-489. No abstract available.

PMID:
19564848
31.

Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques.

Sexton A, De Rose R, Reece JC, Alcantara S, Loh L, Moffat JM, Laurie K, Hurt A, Doherty PC, Turner SJ, Kent SJ, Stambas J.

J Virol. 2009 Aug;83(15):7619-28. doi: 10.1128/JVI.00470-09. Epub 2009 May 13.

32.

Killer T cells in influenza.

Stambas J, Guillonneau C, Kedzierska K, Mintern JD, Doherty PC, La Gruta NL.

Pharmacol Ther. 2008 Nov;120(2):186-96. doi: 10.1016/j.pharmthera.2008.08.007. Epub 2008 Aug 28. Review.

PMID:
18801385
33.

Sindbis virus vectors elicit hemagglutinin-specific humoral and cellular immune responses and offer a dose-sparing strategy for vaccination.

Miller A, Center RJ, Stambas J, Deliyannis G, Doherty PC, Howard JL, Turner SJ, Purcell DF.

Vaccine. 2008 Oct 16;26(44):5641-8. doi: 10.1016/j.vaccine.2008.07.102. Epub 2008 Aug 28.

PMID:
18761047
34.

HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Sealy R, Surman S, Freiden P, Jones B, Martin L, Blanchard J, Slobod KS.

Front Biosci. 2008 Jan 1;13:609-20. Review.

PMID:
17981574
35.

Tracking phenotypically and functionally distinct T cell subsets via T cell repertoire diversity.

Kedzierska K, La Gruta NL, Stambas J, Turner SJ, Doherty PC.

Mol Immunol. 2008 Feb;45(3):607-18. Epub 2007 Aug 24. Review.

36.

Location rather than CD62L phenotype is critical in the early establishment of influenza-specific CD8+ T cell memory.

Kedzierska K, Stambas J, Jenkins MR, Keating R, Turner SJ, Doherty PC.

Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9782-7. Epub 2007 May 23.

37.

A Multi-Vector, Multi-Envelope HIV-1 Vaccine.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Jones B, Surman S, Sealy R, Freiden P, Branum K, Slobod KS.

J Pediatr Pharmacol Ther. 2007 Apr;12(2):68-76. doi: 10.5863/1551-6776-12.2.68.

38.

An in vivo cytotoxicity threshold for influenza A virus-specific effector and memory CD8(+) T cells.

Stambas J, Doherty PC, Turner SJ.

J Immunol. 2007 Feb 1;178(3):1285-92.

39.

A question of self-preservation: immunopathology in influenza virus infection.

La Gruta NL, Kedzierska K, Stambas J, Doherty PC.

Immunol Cell Biol. 2007 Feb-Mar;85(2):85-92. Epub 2007 Jan 9. Review.

PMID:
17213831
40.

Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.

Zhan X, Martin LN, Slobod KS, Coleclough C, Lockey TD, Brown SA, Stambas J, Bonsignori M, Sealy RE, Blanchard JL, Hurwitz JL.

Vaccine. 2005 Nov 16;23(46-47):5306-20. Epub 2005 Jul 20.

PMID:
16095768
41.

HIV vaccines: brief review and discussion of future directions.

Slobod KS, Bonsignori M, Brown SA, Zhan X, Stambas J, Hurwitz JL.

Expert Rev Vaccines. 2005 Jun;4(3):305-13. Review.

PMID:
16026246
42.

Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?

Slobod KS, Coleclough C, Brown SA, Stambas J, Zhan X, Surman S, Jones BG, Zirkel A, Freiden PJ, Brown B, Sealy R, Bonsignori M, Hurwitz JL.

AIDS Res Ther. 2005 Apr 28;2(1):3.

43.

HIV vaccine rationale, design and testing.

Slobod KS, Coleclough C, Bonsignori M, Brown SA, Zhan X, Surman S, Zirkel A, Jones BG, Sealy RE, Stambas J, Brown B, Lockey TD, Freiden PJ, Doherty PC, Blanchard JL, Martin LN, Hurwitz JL.

Curr HIV Res. 2005 Apr;3(2):107-12. Review.

PMID:
15853717
44.

Consequences of immunodominant epitope deletion for minor influenza virus-specific CD8+-T-cell responses.

Andreansky SS, Stambas J, Thomas PG, Xie W, Webby RJ, Doherty PC.

J Virol. 2005 Apr;79(7):4329-39.

45.

Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy.

Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B, Lockey TD, Zirkel A, Freiden P, Brown B, Surman S, Coleclough C, Slobod KS, Doherty PC, Hurwitz JL.

Vaccine. 2005 Mar 31;23(19):2454-64.

PMID:
15752831
46.

Differential tumor necrosis factor receptor 2-mediated editing of virus-specific CD8+ effector T cells.

Turner SJ, La Gruta NL, Stambas J, Diaz G, Doherty PC.

Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3545-50. Epub 2004 Mar 1.

47.

Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity.

Brown SA, Stambas J, Zhan X, Slobod KS, Coleclough C, Zirkel A, Surman S, White SW, Doherty PC, Hurwitz JL.

J Immunol. 2003 Oct 15;171(8):4140-8.

48.

Protection and compensation in the influenza virus-specific CD8+ T cell response.

Webby RJ, Andreansky S, Stambas J, Rehg JE, Webster RG, Doherty PC, Turner SJ.

Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7235-40. Epub 2003 May 29.

49.

Oxidised mannan-listeriolysin O conjugates induce Th1/Th2 cytokine responses after intranasal immunisation.

Stambas J, Pietersz G, McKenzie I, Nagabhushanam V, Cheers C.

Vaccine. 2002 Mar 15;20(13-14):1877-86.

PMID:
11906778
50.

Oxidised mannan as a novel adjuvant inducing mucosal IgA production.

Stambas J, Pietersz G, McKenzie I, Cheers C.

Vaccine. 2002 Jan 15;20(7-8):1068-78.

PMID:
11803067

Supplemental Content

Loading ...
Support Center